DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma



Flinn, Ian W, Miller, Carole B, Ardeshna, Kirit M, Tetreault, Scott, Assouline, Sarit E, Mayer, Jiri, Merli, Michele, Lunin, Scott D, Pettitt, Andrew R, Nagy, Zoltan
et al (show 13 more authors) (2019) DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 37 (11). 912 - +.

[img] Text
jco.18.00915.pdf - OA Published Version

Download (880kB) | Preview
Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 04 Jun 2019 10:23
Last Modified: 14 Sep 2022 02:10
DOI: 10.1200/JCO.18.00915
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3044385